US-based Acutis Diagnostics, a specialised clinical and biosciences company, announced on Tuesday that it has named Dr Abdel Halim as its new chief scientific officer and executive vice president for biopharma and diagnostics services.
Dr Halim has more than 25 years of experience. He has headed biomarker, diagnostic and precision medicine aspects in 150 plus phase 1 to phase three clinical trials belonging to 40 plus development programs with contributions to clinical trial design, conduct, analysis and interpretation. He has served on over 20 CLSI committees to create clinical and laboratory guidelines and authored 12 of them. He is accredited by the FDA as a third-party reviewer of 510k submissions.
In the new role, Dr Halim is to offer scientific leadership to advance clinical product development, cancer genomics and biopharma services.
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer